
Linda A Sherman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/680579/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	The Molecular Basis of Allorecognition. Annual Review of Immunology, 1993, 11, 385-402.	21.8	375
2	CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes. Cancer Research, 2010, 70, 8368-8377.	0.9	368
3	Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex Journal of Experimental Medicine, 1991, 173, 1007-1015.	8.5	297
4	Targeting p53 as a general tumor antigen Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 11993-11997.	7.1	271
5	Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes. Journal of Experimental Medicine, 1997, 185, 833-842.	8.5	252
6	Cellular immune response to adenoviral vector infected cells does not require <i>de novo</i> viral gene expression: Implications for gene therapy. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11377-11382.	7.1	252
7	Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. European Journal of Immunology, 1992, 22, 1013-1022.	2.9	228
8	Peripheral Tolerance of CD8 T Lymphocytes. Immunity, 2005, 22, 275-284.	14.3	211
9	The role of beta 2-microglobulin in peptide binding by class I molecules. Science, 1990, 250, 1423-1426.	12.6	185
10	Phenotypic and Functional Analysis of Cd8+ T Cells Undergoing Peripheral Deletion in Response to Cross-Presentation of Self-Antigen. Journal of Experimental Medicine, 2001, 194, 707-718.	8.5	184
11	Peptide-dependent recognition of H–2Kb by alloreactive cytotoxic T lymphocytes. Nature, 1989, 341, 749-752.	27.8	160
12	Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR. Immunity, 2005, 22, 117-129.	14.3	136
13	Uncoupling of Proliferative Potential and Gain of Effector Function by CD8+ T Cells Responding to Self-Antigens. Journal of Experimental Medicine, 2002, 196, 323-333.	8.5	135
14	Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response Journal of Experimental Medicine, 1989, 170, 1091-1101.	8.5	132
15	Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells. Journal of Immunology, 2008, 180, 3122-3131.	0.8	124
16	Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR. Journal of Immunology, 2005, 175, 5799-5808.	0.8	121
17	The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope. Journal of Experimental Medicine, 1998, 188, 1017-1028.	8.5	120
18	Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Human Immunology, 1997, 52, 109-118.	2.4	101

#	Article	IF	CITATIONS
19	The Use of HLA A2.1/p53 Peptide Tetramers to Visualize the Impact of Self Tolerance on the TCR Repertoire. Journal of Immunology, 2000, 164, 596-602.	0.8	101
20	Ontogeny of T cell tolerance to peripherally expressed antigens. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3854-3858.	7.1	99
21	PTPN22 Alters the Development of Regulatory T Cells in the Thymus. Journal of Immunology, 2012, 188, 5267-5275.	0.8	99
22	Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science, 1992, 258, 815-818.	12.6	98
23	Studies on the mechanism of enzymatic DNA elongation by Escherichia coli DNA polymerase II. Journal of Molecular Biology, 1976, 103, 61-76.	4.2	88
24	Recognition of conformational determinants on H–2 by cytolytic T lymphocytes. Nature, 1982, 297, 511-513.	27.8	83
25	Distinct Requirements for Deletion versus Anergy during CD8 T Cell Peripheral Tolerance In Vivo. Journal of Immunology, 2005, 174, 2046-2053.	0.8	78
26	Memory CD8+ T Cells Undergo Peripheral Tolerance. Immunity, 2002, 17, 73-81.	14.3	75
27	Monoclonal anti-H-2Kb antibodies detect serological differences betweenH-2K b mutants. Immunogenetics, 1981, 12, 183-186.	2.4	71
28	A Spontaneously Arising Pancreatic Tumor Does Not Promote the Differentiation of Naive CD8+T Lymphocytes into Effector CTL. Journal of Immunology, 2004, 172, 6558-6567.	0.8	70
29	Functional differences between low- and high-affinity CD8 ⁺ T cells in the tumor environment. Oncolmmunology, 2012, 1, 1239-1247.	4.6	68
30	Cell-type-specific recognition of allogeneic cells by alloreactive cytotoxic T cells: A consequence of peptide-dependent allorecognition. European Journal of Immunology, 1991, 21, 153-159.	2.9	62
31	Characterization of CD8+ T Lymphocytes That Persist After Peripheral Tolerance to a Self Antigen Expressed in the Pancreas. Journal of Immunology, 2000, 164, 191-200.	0.8	61
32	CD4+ T Cells Pass Through an Effector Phase During the Process of In Vivo Tolerance Induction. Journal of Immunology, 2003, 170, 3945-3953.	0.8	60
33	PTPN22 Controls the Germinal Center by Influencing the Numbers and Activity of T Follicular Helper Cells. Journal of Immunology, 2014, 192, 1415-1424.	0.8	58
34	The Fate of Low Affinity Tumor-Specific CD8+ T Cells in Tumor-Bearing Mice. Journal of Immunology, 2005, 174, 2563-2572.	0.8	51
35	Defective CD8+ T Cell Peripheral Tolerance in Nonobese Diabetic Mice. Journal of Immunology, 2001, 167, 1112-1117.	0.8	50
36	CTLA-4 Blockade Enhances the CTL Responses to the p53 Self-Tumor Antigen. Journal of Immunology, 2001, 166, 3908-3914.	0.8	47

#	Article	lF	CITATIONS
37	Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16683-16688.	7.1	46
38	Cytolytic T-lymphocyte response to isolated class I H–2 proteins and influenza peptides. Nature, 1989, 340, 157-159.	27.8	40
39	The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development. Science Signaling, 2015, 8, ra88.	3.6	39
40	PTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection. Proceedings of the United States of America, 2016, 113, E7231-E7239.	7.1	38
41	A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunology, Immunotherapy, 2004, 53, 345-357.	4.2	37
42	CRISPR-Cas9–Mediated Modification of the NOD Mouse Genome With <i>Ptpn22R619W</i> Mutation Increases Autoimmune Diabetes. Diabetes, 2016, 65, 2134-2138.	0.6	37
43	Deletion of Naive CD8 T Cells Requires Persistent Antigen and Is Not Programmed by an Initial Signal from the Tolerogenic APC. Journal of Immunology, 2003, 171, 6349-6354.	0.8	36
44	Peripheral Tolerance in Transgenic Mice: Tolerance to Class II MHC and non-MHC Transgene Antigens. Immunological Reviews, 1991, 122, 87-102.	6.0	34
45	CD8+ T Cell Tolerance in Nonobese Diabetic Mice Is Restored by Insulin-Dependent Diabetes Resistance Alleles. Journal of Immunology, 2005, 175, 1677-1685.	0.8	33
46	Expression of Diabetes-Associated Genes by Dendritic Cells and CD4 T Cells Drives the Loss of Tolerance in Nonobese Diabetic Mice. Journal of Immunology, 2009, 183, 1533-1541.	0.8	33
47	B7-2 (CD86) Controls the Priming of Autoreactive CD4 T Cell Response against Pancreatic Islets. Journal of Immunology, 2004, 173, 3631-3639.	0.8	31
48	Strategies for Tumor Elimination by Cytotoxic T Lymphocytes. Critical Reviews in Immunology, 1998, 18, 47-54.	0.5	31
49	The T-cell repertoire available for recognition of self-antigens. Current Opinion in Immunology, 2001, 13, 639-643.	5.5	30
50	Contribution of TCR Signaling Strength to CD8+ T Cell Peripheral Tolerance Mechanisms. Journal of Immunology, 2014, 193, 3409-3416.	0.8	28
51	Exogenous β2-microglobulin is required for antigenic peptide binding to isolated class I major histocompatibility complex molecules. European Journal of Immunology, 1991, 21, 2289-2292.	2.9	27
52	Type 1 diabetes pathogenesis is modulated by spontaneous autoimmune responses to endogenous retrovirus antigens in NOD mice. European Journal of Immunology, 2017, 47, 575-584.	2.9	26
53	<i>Idd9.2</i> and <i>Idd9.3</i> Protective Alleles Function in CD4+ T-Cells and Nonlymphoid Cells to Prevent Expansion of Pathogenic Islet-Specific CD8+ T-Cells. Diabetes, 2010, 59, 1478-1486.	0.6	24
54	The Apoptotic Pathway Contributing to the Deletion of Naive CD8 T Cells during the Induction of Peripheral Tolerance to a Cross-Presented Self-Antigen. Journal of Immunology, 2008, 180, 5275-5282.	0.8	20

#	Article	IF	CITATIONS
55	Autoimmunity-Associated LYP-W620 Does Not Impair Thymic Negative Selection of Autoreactive T Cells. PLoS ONE, 2014, 9, e86677.	2.5	20
56	Genetic Interactions among <i>ldd3</i> , <i>ldd5.1</i> , <i>ldd5.2</i> , and <i>ldd5.3</i> Protective Loci in the Nonobese Diabetic Mouse Model of Type 1 Diabetes. Journal of Immunology, 2013, 190, 3109-3120.	0.8	16
57	Genetic and Environmental Regulation of the Cytolytic T Lymphocyte Receptor Repertoire Specific for Alloantigen. Immunological Reviews, 1988, 101, 115-131.	6.0	15
58	The role of Fas-FasL in CD8+ T-cell-mediated insulin-dependent diabetes mellitus (IDDM). Journal of Clinical Immunology, 2001, 21, 15-18.	3.8	15
59	Tissue-Resident Memory CD8+ T Cells Can Be Deleted by Soluble, but Not Cross-Presented Antigen. Journal of Immunology, 2005, 175, 6615-6623.	0.8	14
60	Self-Tolerance and the Composition of T Cell Repertoire. Immunologic Research, 2000, 21, 305-314.	2.9	13
61	In a Transgenic Model of Spontaneous Autoimmune Diabetes, Expression of a Protective Class II MHC Molecule Results in Thymic Deletion of Diabetogenic CD8+ T Cells. Journal of Immunology, 2004, 172, 1000-1008.	0.8	13
62	Fine mapping of type 1 diabetes regions Idd9.1 and Idd9.2 reveals genetic complexity. Mammalian Genome, 2013, 24, 358-375.	2.2	13
63	The effect of the autoimmunity-associated gene, PTPN22, on a BXSB-derived model of lupus. Clinical Immunology, 2015, 156, 65-73.	3.2	12
64	Immunoselection of structural H-2Kb variants: Use of cloned cytolytic T cells to select for loss of a CTL-defined allodeterminant. Immunogenetics, 1986, 23, 52-59.	2.4	11
65	The Use of Idd Congenic Mice to Identify Checkpoints of Peripheral Tolerance to Islet Antigen. Annals of the New York Academy of Sciences, 2007, 1103, 118-127.	3.8	11
66	Ptpn22 and Cd2 Variations Are Associated with Altered Protein Expression and Susceptibility to Type 1 Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 2015, 195, 4841-4852.	0.8	10
67	Proautoimmune Allele of Tyrosine Phosphatase, PTPN22, Enhances Tumor Immunity. Journal of Immunology, 2021, 207, 1662-1671.	0.8	9
68	N-Terminal Trimer Extension of Nominal CD8 T Cell Epitopes Is Sufficient to Promote Cross-Presentation to Cognate CD8 T Cells In Vivo. Journal of Immunology, 2007, 179, 8280-8286.	0.8	8
69	Cellular Mechanisms of Restored Â-Cell Tolerance Mediated by Protective Alleles of Idd3 and Idd5. Diabetes, 2012, 61, 166-174.	0.6	7
70	Altered functional and biochemical response by CD8+ T cells that remain after tolerance. International Immunology, 2001, 13, 1085-1093.	4.0	6
71	To Each (MHC Molecule) Its Own (Binding Motif). Journal of Immunology, 2006, 177, 2739-2740.	0.8	6
72	Immunologic Effects of an Orally Available BRAFV600E Inhibitor in BRAF Wild-type Murine Models. Journal of Immunotherapy, 2012, 35, 473-477.	2.4	6

#	Article	IF	CITATIONS
73	Immunologic Effects of An Oral BRAF Inhibitor in a BRAF Wild-Type Murine Model. Blood, 2011, 118, 4935-4935.	1.4	3
74	Finding order in chaos. Nature Reviews Immunology, 2017, 17, 280-280.	22.7	2
75	Tumor specific CD4 T cells promote the accumulation of low avidity tumor specific CD8 T cells within the tumor milieu. FASEB Journal, 2008, 22, 1076.6.	0.5	1
76	Using Autoimmunity To Inform Tumor Immunity. Journal of Immunology, 2015, 195, 5091-5095.	0.8	0
77	Peripheral Deletion of CD8 T Cells Requires p38 MAPK in Cross-Presenting Dendritic Cells. Journal of Immunology, 2017, 199, 2713-2720.	0.8	0
78	Wendy Havran 1955–2020. Nature Immunology, 2020, 21, 357-357.	14.5	0
79	Nâ€ŧerminal trimer extension of nominal CD8 T cell epitopes is sufficient to promote crossâ€presentation to cognate CD8 T cells in vivo. FASEB Journal, 2008, 22, 1067.16.	0.5	0
80	Using gammaâ€cytokine complexes to improve antigen specific CD8 T cell responses in tumorâ€bearing mice. FASEB Journal, 2008, 22, 1076.3.	0.5	0
81	Restoration of CD8 selfâ€ŧolerance in NOD mice by protective Idd9 genes. FASEB Journal, 2008, 22, 667.25.	0.5	0